ValiRx Plc Company Profile (LON:VAL)

About ValiRx Plc (LON:VAL)

ValiRx Plc logoValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:VAL
  • CUSIP: N/A
  • Web:
  • Market Cap: £1.41 million
  • Outstanding Shares: 130,962,000
Average Prices:
  • 50 Day Moving Avg: GBX 1.83
  • 200 Day Moving Avg: GBX 2.15
  • 52 Week Range: GBX 1 - GBX 11.49
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.03 per share
  • Price / Book: 0.38
  • EBIDTA: ($4,070,000.00)
  • Return on Equity: -200.19%
  • Return on Assets: -122.10%
  • Average Volume: 1.14 million shs.

Frequently Asked Questions for ValiRx Plc (LON:VAL)

What is ValiRx Plc's stock symbol?

ValiRx Plc trades on the London Stock Exchange (LON) under the ticker symbol "VAL."

When will ValiRx Plc make its next earnings announcement?

ValiRx Plc is scheduled to release their next quarterly earnings announcement on Monday, September, 25th 2017. View Earnings Estimates for ValiRx Plc.

Where is ValiRx Plc's stock going? Where will ValiRx Plc's stock price be in 2017?

1 analysts have issued 1-year target prices for ValiRx Plc's stock. Their predictions range from GBX 6.50 to GBX 6.50. On average, they expect ValiRx Plc's stock price to reach GBX 6.50 in the next year. View Analyst Ratings for ValiRx Plc.

Who are some of ValiRx Plc's key competitors?

Who are ValiRx Plc's key executives?

ValiRx Plc's management team includes the folowing people:

  • Satu Vainikka, Chief Executive Officer, Director
  • Gerald Desler, Chief Financial Officer, Director
  • George Morris, Chief Operating Officer, Director
  • Kevin John Alexander, Secretary, Non-Executive Director
  • Oliver de Giorgio-Miller, Non-Executive Chairman of the Board
  • Seppo Olavi Makinen, Non-Executive Director

How do I buy ValiRx Plc stock?

Shares of ValiRx Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ValiRx Plc's stock price today?

One share of ValiRx Plc stock can currently be purchased for approximately GBX 1.08.

MarketBeat Community Rating for ValiRx Plc (LON VAL)
Community Ranking:  1.2 out of 5 (star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  185
MarketBeat's community ratings are surveys of what our community members think about ValiRx Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ValiRx Plc (LON:VAL) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: GBX 6.50

Analysts' Ratings History for ValiRx Plc (LON:VAL)
DateFirmActionRatingPrice TargetDetails
9/8/2017Beaufort SecuritiesReiterated RatingSpeculative BuyGBX 6.50View Rating Details
12/8/2016Northland SecuritiesReiterated RatingCorporateView Rating Details
11/5/2015Northland Capital PartnersReiterated RatingcorporateView Rating Details
(Data available from 9/19/2015 forward)


Earnings History for ValiRx Plc (LON:VAL)
No earnings announcements for this company have been tracked by


Earnings Estimates for ValiRx Plc (LON:VAL)
Current Year EPS Consensus Estimate: $0.000 EPS


Dividend History for ValiRx Plc (LON:VAL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ValiRx Plc (LON:VAL)
No insider trades for this company have been tracked by


Headline Trends for ValiRx Plc (LON:VAL)
Latest Headlines for ValiRx Plc (LON:VAL)
DateHeadline logoValiRx Sees Good Progress In GeneICE Technology Development - September 7 at 10:46 AM logoValiRX Draws Down USD400,000 From Convertible Loan Facility - August 12 at 1:48 AM logoValiRX Draws Down USD400,000 From Convertible Loan Facility - London South East (registration) (blog) - August 11 at 3:43 PM logoValiRx Says YA Global Master Converts USD250,000 Of Loan Notes (ALLISS) - London South East (registration) (blog) - August 4 at 9:38 AM logoValiRX Signs Licensing Deal With Bangladesh's Mystic Pharmaceuticals - July 29 at 8:20 AM logoValiRx Advisory Board Formed Of Existing, Former And New Individuals - June 23 at 12:32 AM logoBeaufort Securities Reaffirms "Speculative Buy" Rating for ValiRx Plc (VAL) - June 17 at 11:44 AM logoValiRx Completes VAL401 Lung Cancer Study Recruitment - June 15 at 3:17 PM logoValiRx Plc's (VAL) Speculative Buy Rating Reaffirmed at Beaufort Securities - May 28 at 8:56 PM logoBeaufort Securities Reiterates Speculative Buy Rating for ValiRx Plc (VAL) - May 27 at 2:34 PM logoValiRx Plc (VAL) Rating Reiterated by Beaufort Securities - May 8 at 7:05 AM logoCompany Overview of Azure Holdings plc - March 28 at 9:09 PM logoValiRx Plc (VAL) Receives Speculative Buy Rating from Beaufort Securities - March 16 at 2:30 AM logoVAL. With Val 401 d- - March 9 at 4:08 AM logoValiRx Says "Significant" Progression Made With VAL401 Trial - March 9 at 4:08 AM logoValiRx Shares Drop On Discounted Placing To Progress Trial Development (ALLISS) - March 3 at 5:11 AM logoGlobal Endometriosis Industry - February 27 at 5:19 PM logoValiRx Takes More Funds From Loan Facility To Progress Trials - December 3 at 9:37 AM logoValiRx Makes Progress With Second Clinical Testing Site For VAL401 - December 2 at 10:28 AM


Social activity is not available for this stock.


ValiRx Plc (VAL) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff